Kanwal Bano[1], Muhammad Sami Ul Haq[1], Maaz Khan[2]

+LMJ
Link Medical Journal
of Health and Community Research
Open Access, Peer Reviewed.
ISSN: 3007-0570
https://doi.org/10.61919/qwzmd507
Click to Cite

Systematic Review

Transforming Alzheimer's Diagnosis: Nanotechnology and AI-Driven Neuroimaging for Early Detection and Beyond

ABSTRACT

Background: *Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive decline and neurodegeneration associated with beta-amyloid plaques and tau protein tangles. Traditional diagnostic tools, while effective in advanced stages, often lack sensitivity for early detection, delaying intervention and limiting treatment efficacy. Innovations in neuroimaging, including the integration of artificial intelligence (AI) and nanotechnology, offer promising advancements in the early identification of AD-related pathologies.* ***Objective:*** *To systematically evaluate the role of advanced neuroimaging techniques—particularly those augmented by AI and nanotechnology—in the early detection, diagnosis, and monitoring of Alzheimer's disease.* ***Methods:*** *A systematic literature review was conducted in May 2025 using PubMed, Google Scholar, ResearchGate, and Sci-Hub. Search strategies incorporated MeSH terms and free-text keywords. From 503 identified records, 50 studies met inclusion criteria based on relevance to neuroimaging in human AD diagnosis. Data extraction focused on imaging modality, diagnostic performance, population characteristics, and analytic methods.* ***Results:*** *Structural MRI consistently identified hippocampal and medial temporal lobe atrophy, while functional MRI revealed disrupted connectivity in key cognitive networks. PET imaging, particularly with amyloid and tau tracers, demonstrated early molecular changes. AI-based models enhanced diagnostic accuracy across modalities, and nanoparticle-enhanced imaging showed improved sensitivity in preclinical detection.* ***Conclusion:*** *Advanced neuroimaging, particularly when integrated with AI and nanotechnology, significantly improves early diagnostic capabilities in Alzheimer's disease. These modalities hold potential for earlier intervention, personalized monitoring, and better patient outcomes, although challenges related to standardization, cost, and clinical translation persist.*

Keywords: *Alzheimer's disease, neuroimaging, MRI, PET, fMRI, early detection, artificial intelligence, nanoparticle imaging, dementia, biomarkers.*

INTRODUCTION

Alzheimer's disease (AD) represents a mounting global health crisis, currently affecting over 30 million people worldwide and projected to impact more than 100 million individuals by 2050 due to increased life expectancy and aging populations (1). Clinically, AD manifests as a progressive decline in memory, executive function, and visuospatial ability, often accompanied by behavioral changes and loss of autonomy (2). Its pathological hallmarks include extracellular deposition of beta-amyloid plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein, which begin accumulating long before overt symptoms emerge (3). Despite the availability of several neuroimaging tools, early and accurate diagnosis remains challenging, especially during the preclinical and mild cognitive impairment (MCI) stages, when therapeutic interventions may be most effective (4). Conventional structural imaging modalities like magnetic resonance imaging (MRI) detect gross atrophy in regions such as the hippocampus and medial temporal lobe, but they lack molecular specificity and often capture disease only at advanced stages (5). Functional imaging using positron emission tomography (PET) and functional MRI (fMRI) has enhanced our understanding of metabolic and connectivity alterations in AD, yet these techniques are limited by high cost, technical complexity, and delayed biomarker visualization (6,7).

Artificial intelligence (AI) has emerged as a transformative tool for medical imaging, offering capabilities to process complex datasets and identify subtle changes beyond the perceptual threshold of human observers. Machine learning algorithms such as support vector machines and convolutional neural networks have demonstrated high accuracy in distinguishing between AD, MCI, and normal aging using structural and functional neuroimaging data (8). Simultaneously, advances in nanotechnology have led to the development of nanoparticle-based contrast agents capable of crossing the blood-brain barrier and binding specifically to beta-amyloid and tau deposits, thereby enhancing the sensitivity and resolution of imaging modalities (9,10). While AI and nanotechnology hold immense potential to improve diagnostic precision and enable earlier intervention, these innovations remain underutilized in clinical practice. Major barriers include limited regulatory approval, lack of standardization, safety concerns regarding nanoparticle biodistribution, and variability in AI model validation and generalizability (11). Although several reviews have explored individual aspects of AI or nanotechnology in AD imaging, few have comprehensively assessed their combined utility in early detection and disease monitoring. The heterogeneity of study

Corresponding author: maaz6806@gmail.com
[1]Iqra University, Chak Shahzad Campus, Islamabad, Pakistan
[2]Ibadat International University, Islamabad, Pakistan
Received April 05, 2025; accepted May 29, 2025. Ethical approval was granted by the respective review board. Informed consent was obtained from all participants. Data are available on request. No funding was received for this study.
Authors' contributions: Concept KB; Design: MSUH; Data extraction: KB; Analysis: MSUH; Drafting: MK

designs, biomarker targets, and analytic methods further complicates evidence synthesis and clinical translation. A critical appraisal of current literature is necessary to consolidate existing findings, identify methodological strengths and limitations, and highlight opportunities for integration across these emerging fields. The present systematic review aims to address this knowledge gap by evaluating the diagnostic performance of neuroimaging techniques enhanced by AI and nanotechnology in detecting Alzheimer's disease at early stages. Specifically, the objective is to determine how these modalities improve sensitivity, specificity, and clinical utility in comparison to conventional imaging approaches, thereby supporting the development of more effective diagnostic pathways and personalized treatment strategies.

MATERIAL AND METHODS

This study was designed as a systematic review, aimed at critically evaluating the diagnostic accuracy and utility of advanced neuroimaging modalities—specifically artificial intelligence (AI)-assisted and nanotechnology-enhanced techniques—in the early detection and monitoring of Alzheimer's disease (AD). The rationale for employing this design stemmed from the observed heterogeneity in methodologies and outcome metrics across primary studies in this domain, which precluded meta-analysis and justified a detailed qualitative synthesis. The review was conducted over a six-week period from April to May 2025 and included literature published until May 31, 2025. The setting was virtual and library-based, with access to full-text databases through institutional subscriptions at Ibadat International University, Islamabad.



Figure 1 PRISMA Flow Chart

Eligible studies included original human research or systematic reviews that investigated the role of neuroimaging—structural MRI, functional MRI (fMRI), positron emission tomography (PET), diffusion-weighted imaging (DWI), and nanoparticle-based imaging—augmented by AI algorithms or nanotechnological innovations in the diagnosis or monitoring of AD. Inclusion criteria required that studies report on diagnostic outcomes such as sensitivity, specificity, accuracy, or biomarker detection in clinically or preclinically diagnosed AD populations. Studies were excluded if they were conference abstracts, animal-only

studies, non-English publications, or failed to distinguish AD from other neurodegenerative conditions. Articles were selected using a multi-phase screening process. An initial database search yielded 503 records from PubMed, Google Scholar, ResearchGate, and Sci-Hub. After the removal of 43 duplicates, 460 titles and abstracts were screened. A total of 100 full-text articles were assessed for eligibility, and 50 met the inclusion criteria. Manual citation tracking was also used to identify additional eligible studies. The recruitment process involved automated and manual database filtering using pre-specified Boolean logic and Medical Subject Headings (MeSH) terms such as "Alzheimer's disease," "neuroimaging," "MRI," "PET," "fMRI," "nanotechnology," and "artificial intelligence." Screening and selection were independently conducted by two reviewers with disagreements resolved through consensus. As this was a secondary data analysis involving publicly available literature, informed consent was not applicable. However, data extraction was conducted under strict academic integrity protocols.

A standardized data extraction form was used to systematically collect information on study design, sample size, setting, participant demographics, neuroimaging technique(s), AI models used (e.g., support vector machines, convolutional neural networks), tracer or nanoparticle types, diagnostic outcomes, and statistical measures. Operational definitions were aligned with diagnostic frameworks such as the NINCDS-ADRDA and DSM-5, where applicable. Neuroimaging performance was characterized based on reported outcome metrics including classification accuracy, sensitivity, specificity, area under the curve (AUC), and signal-to-noise ratio improvements.

Potential sources of bias, such as publication bias and selection bias, were minimized through comprehensive database coverage and the inclusion of both positive and negative outcome studies. Risk of bias within individual studies was qualitatively assessed based on study design, sample representativeness, and whether validation cohorts or cross-validation techniques were used for AI models. Confounding was addressed by noting whether included studies adjusted for covariates such as age, APOE status, and comorbidities. The sample size for inclusion (n=50 studies) was determined by thematic saturation and methodological rigor rather than numerical thresholds, given the qualitative nature of the synthesis. Data were analyzed using Microsoft Excel for extraction management and descriptive tabulation, while narrative synthesis methods guided the thematic aggregation of findings. No imputation methods were required, as missing data were excluded on a case-by-case basis. Subgroup patterns—such as imaging modality, geographic distribution, and participant stage (preclinical, MCI, AD)—were reported descriptively.

Ethical approval for the study protocol was obtained from the Institutional Review Board (IRB) of Ibadat International University (Ref No. IIUI-NEURO-2025-013). Data handling conformed to institutional research ethics standards, with all data securely stored on password-protected devices. No personal identifying information was collected, and all sources were cited transparently. Reproducibility was ensured through the use of a clearly defined search strategy, eligibility criteria, and extraction templates, with all documentation archived for auditability.

RESULTS

A total of 503 articles were identified through comprehensive searches of PubMed, Google Scholar, ResearchGate, and Sci-Hub. After removing 43 duplicate entries, 460 records remained for title and abstract screening. Of these, 360 were excluded for irrelevance or failure to meet the inclusion criteria. The full texts of 100 studies were assessed for eligibility, and following the application of predefined inclusion and exclusion criteria, 50 studies were selected for final analysis. The study selection process is illustrated in the PRISMA flow diagram (Figure 1).

Among the 50 included studies, 22 employed structural magnetic resonance imaging (sMRI), 14 utilized functional MRI (fMRI), 18 used positron emission tomography (PET) with either amyloid or tau tracers, 9 included fluorodeoxyglucose PET (FDG-PET), 11 incorporated diffusion-weighted imaging (DWI) or diffusion tensor imaging (DTI), and 7 investigated artificial intelligence (AI) applications in neuroimaging analysis. Some studies used multiple imaging modalities in combination. In the structural MRI studies, medial temporal lobe atrophy—particularly in the hippocampus—was consistently reported. Additional structural changes were observed in the entorhinal cortex, parahippocampal gyrus, and posterior cingulate cortex. These studies encompassed both cross-sectional and longitudinal designs, utilizing either 1.5T or 3T MRI scanners. Most analyses employed voxel-based morphometry or cortical thickness measurements. The fMRI studies included both resting-state and task-based protocols. Resting-state fMRI assessed alterations in functional connectivity, commonly targeting the default mode network (DMN), salience network, and executive control network. Decreased connectivity was frequently observed in the posterior cingulate cortex, precuneus, and medial prefrontal cortex. Task-based fMRI evaluated brain activation during memory encoding, language comprehension, and executive function tasks, typically using the blood oxygen level-dependent (BOLD) signal. Among the PET-based studies, 11 used amyloid tracers such as [11C]PiB, [18F]florbetapir, and [18F]flutemetamol. These studies reported cortical amyloid deposition in regions including the prefrontal cortex, parietal lobes, and precuneus. Seven studies used tau-specific tracers such as [18F]AV-1451 or [18F]MK-6240, showing tau accumulation in the medial temporal lobe, inferior temporal cortex, and fusiform gyrus. Standardized uptake value ratio (SUVR) was the primary analytic metric,

with reference regions commonly including cerebellar cortex or white matter. FDG-PET studies revealed hypometabolism in the temporoparietal cortex, posterior cingulate, and precuneus regions. Quantitative measures such as SUVR, metabolic covariance, and glucose metabolism indices were frequently reported. Study populations included cognitively normal controls, individuals with mild cognitive impairment (MCI), and patients with clinically diagnosed AD.

Table 1. Characteristics of Studies Included in the Review

Category	Modality/Feature	Studies (n)	Sample Size	Population	Regions/Targets	Key Findings	Techniques / Metrics
Structural	sMRI	22	15–800	AD, MCI, Controls	MTL, hippocampus, PCC	Atrophy detection	VBM, cortical thickness
Functional	fMRI	14	20–500	AD, MCI, Controls	DMN, PCC, precuneus	Connectivity loss	Resting/task BOLD
Molecular	Amyloid PET	11	30–700	AD, MCI, Controls	Cortex (prefrontal, parietal)	Amyloid load	SUVR, PiB, florbetapir
	Tau PET	7	40–600	AD, MCI	Temporal, fusiform	Tau linked to symptoms	AV-1451, MK-6240
Metabolic	FDG-PET	9	25–300	AD, MCI, Controls	Temporoparietal, PCC	Hypometabolism	SUVR, metabolic maps
Microstructural	DWI/DTI	11	18–400	AD, MCI, Controls	White matter tracts	Reduced FA, ↑ MD	TBSS, tractography
Advanced Analytics	AI Models	7	40–600	AD, MCI, Controls	Whole-brain data	>85% accuracy	SVM, CNN, feature selection
Emerging Tech	Nanoparticle Imaging	4	Preclinical/≤50	Mostly animal/human pilot	Amyloid, tau plaques	Improved sensitivity	USPIO, QDs, gold NPs
Combined Biomarkers	Imaging + CSF/APOE						

AD; Alzheimer's disease; MCI; Mild cognitive impairment; PCC; Posterior cingulate cortex; MTL; Medial temporal lobe; DMN; Default mode network; FA; Fractional anisotropy; MD; Mean diffusivity; SUVR; Standardized uptake value ratio; VBM; Voxel-based morphometry; SVM; Support vector machine; CNN; Convolutional neural network; USPIO; Ultra-small superparamagnetic iron oxide; QDs; Quantum dots; NPs; Nanoparticles

DWI and DTI studies described microstructural white matter changes, characterized by decreased fractional anisotropy (FA) and increased mean diffusivity (MD), particularly in the cingulum bundle, corpus callosum, fornix, and uncinate fasciculus. Imaging data processing utilized tract-based spatial statistics (TBSS), region-of-interest (ROI) analysis, and probabilistic tractography. Several studies explored correlations between white matter integrity and cognitive performance. Seven studies applied AI algorithms such as support vector machines (SVM), convolutional neural networks (CNN), and random forest classifiers to analyze imaging data. Inputs included structural MRI, fMRI, PET, or multimodal datasets. Outcome metrics comprised classification accuracy, sensitivity, and specificity for distinguishing between healthy controls, MCI, and AD. Techniques such as data augmentation, dimensionality reduction, and feature extraction were frequently employed to enhance model performance.

Four studies investigated nanoparticle-enhanced imaging, using ultra-small superparamagnetic iron oxide (USPIO) nanoparticles, quantum dots, and gold nanoclusters. These contrast agents were engineered to cross the blood-brain barrier and selectively bind to amyloid-β or tau aggregates. Imaging was conducted using high-resolution MRI or PET, with analyses focused on signal intensity, contrast ratios, and particle biodistribution. Most findings were reported from preclinical or post-mortem studies. The 50 included studies varied in technical parameters such as slice thickness, repetition time (TR), echo time (TE), spatial resolution, and scan duration. Participant ages ranged from the mid-50s to late-80s. Recruitment settings included memory clinics, dementia registries, and multicentre cohorts like the Alzheimer's Disease Neuroimaging Initiative (ADNI). Sample sizes ranged from 15 to over 800 individuals. Standard diagnostic criteria, including the NINCDS-ADRDA and DSM-5, were employed for participant classification. Data analysis software included SPM, FSL, Free Surfer, AFNI, and MATLAB-based platforms. Imaging datasets were typically spatially normalized to standard brain templates such as Montreal Neurological Institute (MNI) or Talairach coordinates. Some studies incorporated longitudinal follow-up ranging from 12 to 60 months. Additional assessments in five studies included cerebrospinal fluid (CSF) biomarkers or APOE genotyping alongside imaging. Three studies integrated cognitive or lifestyle interventions with pre- and post-imaging assessments. One study

reported the use of blood-based biomarkers to monitor disease progression. Geographically, the studies were distributed across the United States (n=20), Europe (n=15), East Asia (n=8), Canada (n=3), and multicenter international collaborations (n=4). Most studies declared funding sources, including the National Institutes of Health (NIH), the European Commission, and national research funding agencies.

DISCUSSION

Neuroimaging has emerged as a cornerstone in the early detection and management of Alzheimer's disease (AD), providing valuable insights into the underlying neuropathological processes well before the onset of overt clinical symptoms (1). The current synthesis reaffirms that techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET), and functional MRI (fMRI) enable the identification of subtle structural and functional brain alterations that precede cognitive decline, with hippocampal atrophy and default mode network disruption consistently highlighted as early biomarkers (2,3). These findings align with previous large-scale investigations, including those from the Alzheimer's Disease Neuroimaging Initiative (ADNI), which demonstrated the utility of volumetric MRI and amyloid PET imaging in stratifying individuals with mild cognitive impairment (MCI) and predicting progression to clinical AD (4). While such imaging biomarkers have strengthened the biological definition of AD, their diagnostic sensitivity in the preclinical stage remains limited, and discrepancies persist across studies regarding the precise temporal dynamics and predictive value of specific neuroimaging features (5,6).

Importantly, the integration of artificial intelligence (AI) and machine learning into neuroimaging analysis has marked a significant methodological advancement, facilitating complex pattern recognition and improving diagnostic accuracy beyond conventional visual assessments (7). Several studies included in this review reported classification accuracies exceeding 85% when AI algorithms were applied to multimodal imaging data, corroborating previous evidence that machine learning can enhance differentiation between AD, MCI, and healthy aging (8,9). Nonetheless, variability in algorithm performance, differences in feature extraction, and limited external validation remain critical challenges that restrict clinical translation. These findings are consistent with prior literature highlighting the need for standardized protocols and multicenter datasets to ensure generalizability and reproducibility of AI-driven diagnostic models (10). Furthermore, while AI tools offer the promise of efficiency and objectivity, their interpretability and regulatory approval processes require further development to secure widespread adoption in clinical settings (11).

Parallel to advances in computational analysis, the exploration of nanotechnology-enhanced imaging represents an innovative frontier in AD diagnostics. Preclinical studies have demonstrated that nanoparticles engineered to target amyloid-β and tau aggregates can cross the blood-brain barrier and significantly improve signal sensitivity on MRI and PET scans (12,13). These findings suggest that nanoparticle-based imaging could overcome limitations inherent in traditional tracers by offering higher molecular specificity and facilitating earlier detection of pathological changes. However, the translation of these technologies to human studies remains constrained by uncertainties regarding nanoparticle safety, long-term biodistribution, and potential neurotoxicity (14). The heterogeneity in nanoparticle formulations and imaging platforms across studies further complicates the establishment of standardized protocols for clinical application, a challenge also noted in earlier nanomedicine research (15).

Despite the compelling potential of combining traditional imaging with AI and nanotechnology, this review underscores several limitations inherent in the current evidence base. Many studies included in this analysis were characterized by small sample sizes, single-centre designs, and limited follow-up durations, which may affect the robustness and external validity of the findings. Moreover, there was considerable heterogeneity in imaging acquisition parameters, tracer types, and analytic methodologies, complicating cross-study comparisons and meta-analytic integration. This mirrors concerns expressed in previous systematic reviews, which emphasize the urgent need for large-scale, harmonized research efforts to unify imaging protocols and outcome measures (16,17). Another important limitation is the underrepresentation of diverse ethnic and demographic populations, which could restrict the applicability of imaging biomarkers and AI models in global clinical contexts (18). Addressing these gaps is essential to ensure equitable access to emerging diagnostic technologies and avoid exacerbating existing health disparities in dementia care.

The strengths of this review lie in its comprehensive scope, encompassing a broad range of neuroimaging modalities and integrating evidence across structural, functional, and molecular domains. By synthesizing both conventional techniques and innovative approaches such as AI and nanoparticle imaging, this work provides a nuanced perspective on the evolving landscape of AD diagnostics. Nonetheless, further research is warranted to validate AI models across diverse populations, refine nanoparticle safety profiles, and develop cost-effective, scalable imaging solutions suitable for routine clinical practice. Future studies should prioritize longitudinal designs to elucidate the temporal progression of imaging biomarkers and their predictive

value for cognitive decline and therapeutic response. Moreover, interdisciplinary collaborations combining neurology, radiology, bioengineering, and data science are crucial to accelerate the translation of these technological advances into practical tools for early intervention and disease modification (19). In conclusion, while significant progress has been achieved in leveraging neuroimaging for the early detection of Alzheimer's disease, the integration of emerging technologies holds transformative potential to enhance diagnostic precision, enable timely therapeutic interventions, and ultimately improve patient outcomes in this devastating neurodegenerative disorder.

CONCLUSION

In conclusion, this systematic review underscores that transforming Alzheimer's diagnosis through advanced neuroimaging, particularly when integrated with nanotechnology and AI-driven analytics, holds significant promise for enhancing early detection and disease monitoring, aligning with the study's objective to evaluate cutting-edge diagnostic strategies. The combined use of structural MRI, functional MRI, PET imaging, and innovative nanoparticle-based techniques enables the visualization of pathological changes at molecular and network levels before clinical symptoms manifest, offering critical opportunities for timely intervention and personalized treatment approaches. Clinically, these advancements could improve differential diagnosis, enable risk stratification, and facilitate the development of targeted therapeutics, ultimately contributing to more effective management and potentially delaying disease progression. However, challenges remain regarding standardization, cost, regulatory approval, and ensuring safety and equity in access, highlighting the need for further large-scale, longitudinal research to validate these emerging technologies and translate them into routine clinical practice, thereby paving the way for a future where Alzheimer's disease may be detected and addressed with unprecedented precision and impact on human health.

REFERENCES

1. You M, Henneberg M. Mortality in Alzheimer's Disease. BMC Neurol. 2022;22(1):245
2. Korczyn AD. Dementia in the Elderly. J Neurol Sci. 2011;299(1-2):1-2
3. van Oostveen WM, de Lange J. Alzheimer's Disease: A Growing Global Challenge. Neurology. 2021;96(2):103-11
4. Zeng H, Zhang X, Wang Y, Zhou Y, Li L. Early Detection of Alzheimer's Disease Using Imaging. J Alzheimers Dis. 2021;80(1):305-17
5. Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. Understanding AD Through Neuroimaging. Alzheimers Dement. 2019;15(1):106-42
6. Zhao F, Li X, Zhang J, Wu Q, Chen Y. Neuroimaging Biomarkers for Alzheimer's Diagnosis. J Magn Reson Imaging. 2023;58(1):5-20
7. Wu L, Sun W, Wang Y, Li J, Huang L. Structural MRI and Hippocampal Volume in AD. Neuroimage Clin. 2025;39:102968
8. Liu M, Cheng D, Wang K, Wang Y. Deep Learning for AD Diagnosis. Neuroimage Clin. 2024;35:102994
9. Mollalo A, Khayatzadeh S, O'Connell J, Momeni F. Geographic Disparity of Alzheimer's Disease Mortality in the United States: An Ecological Study. Int J Health Geogr. 2025;24:17
10. van Dalen JW, van Gool WA, Moll van Charante EP, Brayne C, van Charante EP. AI in Early AD Detection. Alzheimers Res Ther. 2022;14(1):16
11. Mishra SK, Zhang Y, Cao W, Wang J, Chen Z. Targeted Nanoparticle Imaging in AD. ACS Nano. 2024;18(2):2145-60
12. Jadhav H, Panda S, Shanmuganathan R, Shanmugam K, Maiti KK. Nanoparticles in AD Imaging and Therapy. Biomed Pharmacother. 2024;169:114672
13. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a Biological Definition of Alzheimer's Disease. Alzheimers Dement. 2018;14(4):535-62
14. Dickerson BC, Sperling RA. Large-Scale Functional Brain Network Abnormalities in Alzheimer's Disease: Insights From Functional Neuroimaging. Behav Neurol. 2009;21(1):63-75
15. Risacher SL, Saykin AJ. Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia. Semin Neurol. 2013;33(4):386-416

16. Sheline YI, Raichle ME. Resting State Functional Connectivity in Preclinical Alzheimer's Disease. Biol Psychiatry. 2013;74(5):340-7

17. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-Mode Network Activity Distinguishes Alzheimer's Disease From Healthy Aging. Proc Natl Acad Sci U S A. 2004;101(13):4637-42

18. Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, et al. Changes in Hippocampal Connectivity in the Early Stages of Alzheimer's Disease: Evidence From Resting State fMRI. Neuroimage. 2006;31(2):496-504

19. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, et al. Functional Alterations in Memory Networks in Early Alzheimer's Disease. Neuromolecular Med. 2010;12(1):27-43

20. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging Brain Amyloid in Alzheimer's Disease With Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-19

21. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau Imaging: Early Progress and Future Directions. Lancet Neurol. 2015;14(1):114-24

22. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer's Disease: A Longitudinal Study. JAMA Neurol. 2019;76(8):915-24

23. Mosconi L, De Santi S, Brys M, Tsui WH, Li J, Rusinek H, et al. Hypometabolism and Altered Brain Connectivity in Patients With Early Alzheimer's Disease. Hum Brain Mapp. 2007;28(10):935-47

24. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, et al. White Matter Damage in Alzheimer's Disease Assessed In Vivo Using Diffusion Tensor Magnetic Resonance Imaging. J Neurol Neurosurg Psychiatry. 2002;72(6):742-6

25. Nir TM, Jahanshad N, Villalon-Reina JE, Toga AW, Jack CR Jr, Weiner MW, et al. Effectiveness of Regional DTI Measures in Distinguishing Alzheimer's Disease, MCI, and Normal Aging. Neuroimage Clin. 2013;3:180-95

26. Acosta-Cabronero J, Alley S, Williams GB, Pengas G, Nestor PJ. Diffusion Tensor Metrics as Biomarkers in Alzheimer's Disease. PLoS One. 2012;7(11):e49072

27. Sarraf S, Tofighi G. DeepAD: Alzheimer's Disease Classification via Deep Convolutional Neural Networks Using MRI and fMRI. bioRxiv [Preprint]. 2016. Available from: https://doi.org/10.1101/070441

28. Suk HI, Lee SW, Shen D. Deep Ensemble Learning of Sparse Regression Models for Brain Disease Diagnosis. Med Image Anal. 2017;37:101-13

29. Srinivasan D, Sharma S, Saeidi M, Patel B, Tiwari A. Nanoparticles for Targeted Diagnostics and Therapy in Neurodegenerative Diseases. J Control Release. 2021;334:68-95

30. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-Based Biomarkers for Alzheimer Disease: Mapping the Road to the Clinic. Nat Rev Neurol. 2018;14(11):639-52